WO1994027449A1 - Monohydrate dextrose or glucose composition - Google Patents
Monohydrate dextrose or glucose composition Download PDFInfo
- Publication number
- WO1994027449A1 WO1994027449A1 PCT/NZ1994/000042 NZ9400042W WO9427449A1 WO 1994027449 A1 WO1994027449 A1 WO 1994027449A1 NZ 9400042 W NZ9400042 W NZ 9400042W WO 9427449 A1 WO9427449 A1 WO 9427449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- composition
- homeopathic
- potency
- titration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title claims abstract description 14
- 239000008121 dextrose Substances 0.000 title claims abstract description 11
- 150000004682 monohydrates Chemical class 0.000 title claims abstract description 11
- 239000008103 glucose Substances 0.000 title claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000001632 homeopathic effect Effects 0.000 claims abstract description 9
- 238000004448 titration Methods 0.000 claims abstract description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 7
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 7
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 7
- 239000011787 zinc oxide Substances 0.000 claims abstract description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 6
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 6
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 6
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 6
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 6
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 206010019133 Hangover Diseases 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 6
- 159000000001 potassium salts Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition for the treatment of a "hangover" i.e. the after-effects of excessive consumption of ethyl alcohol by a human being.
- An object of the invention is the provision of a composition which can be taken as a single treatment (in one or more doses) to counteract a hangover.
- the present invention provides a composition including:- a major proportion of monohydrate dextrose or glucose in combination with the following compounds:
- liver activity As the liver increases its normal rate of breaking down glycogen into blood sugar, to restore the optimum blood sugar level.
- Continual or frequent such increase in liver activity can lead to cirrhosis of the liver.
- the brain uses about 25% of available blood sugar, and so is particularly rapidly effected by a drop in blood sugar levels:- hence the symptoms of slurred speech, memory lapses, headaches, loss of co-ordination, blurred vision, personality changes, and so on commonly associated with alcohol consumption.
- Monohydrate dextrose breaks down to glucose in the body, and thus both monohydrate dextrose and glucose are quickly and readily assimilated into the blood stream to boost the blood sugar level and help prevent liver damage and counteract brain disfunction.
- magnesium and potassium salts are magnesium sulphate, magnesium oxide, and potassium phosphate.
- magnesium and potassium salts may be used.
- magnesium and potassium salts and vitamin C are much more readily and easily absorbed into the system if taken into the system with monohydrate dextrose or glucose:- the monohydrate dextrose or glucose effectively coats said other constituents and prevents them from being destroyed by stomach acids, and also speeds their circulation around the system.
- Zinc oxide assists the pancreas with the production of insulin, and hence facilitates the absorption of glucose into the blood.
- Zinc oxide also is known to be effective in detoxifying the system i.e. combatting the after-effects of alcohol.
- vitamin B6 in the composition considerably increases the rate of activity of the composition and thus gives more rapid relief to a user. It appears that vitamin B6 and magnesium salts are synergistic i.e. the presence of one increases the effectiveness of the other, and thus reduces the amount of each needed in the composition to achieve the desired effect.
- the constituents of the composition act to raise the user's blood sugar level and replenish lost vitamin C, magnesium and potassium, and also interact with each other to mutually increase their effectiveness and to speed their assimilation into the system.
- composition also may contain one or more of the following:
- a preferred embodiment of the present composition comprises:
- the composition is in the form of a powder, and is taken dissolved in water or in tablet form. It has been found that the composition is more effective if the user lies on the right side after taking the composition, because this allows the composition to pass more quickly though the duodenum into the intestine, for absorption into the system.
- the composition may be prepared in liquid form, and drunk or given by injection.
Abstract
A composition for the treatment of a hangover in a human being, consisting of a composition including: a major proportion of monohydrate dextrose or glucose in combination with the following compounds: 0.5% - 2% by weight ascorbic acid; a non-toxic potassium salt in a homeopathic titration to the 6 C potency or up to 0.4% by weight; a non-toxic magnesium salt in a homeopathic titration to the 6 C potency or up to 0.4% by weight; 0.0001% - 2.5% by weight vitamin B6; zinc oxide in a homeopathic titration to the 6 C potency or up to 0.07% by weight.
Description
TITLE: MONOHYDRATE DEXTROSE OR GLUCOSE COMPOSITION Background of the invention
The present invention relates to a composition for the treatment of a "hangover" i.e. the after-effects of excessive consumption of ethyl alcohol by a human being.
Summary of the Invention
An object of the invention is the provision of a composition which can be taken as a single treatment (in one or more doses) to counteract a hangover.
The present invention provides a composition including:- a major proportion of monohydrate dextrose or glucose in combination with the following compounds:
(a) 0.5% - 2% by weight ascorbic acid; (b) a non-toxic potassium salt in a homeopathic titration to the 6 C potency or up to 0.4% by weight;
(c) a non-toxic magnesium salt in a homeopathic titration to the 6 C potency or up to 0.4% by weight;
(d) 0.001% - 2.5% by weight vitamin B6;
(e) zinc oxide in a homeopathic titration to the 6 C potency or up to 0.07% by weight.
Detailed Description of the Invention
One of the known effects of alcohol in the human system is to lower the blood sugar, and this leads to an increase in
liver activity as the liver increases its normal rate of breaking down glycogen into blood sugar, to restore the optimum blood sugar level. Continual or frequent such increase in liver activity can lead to cirrhosis of the liver. The brain uses about 25% of available blood sugar, and so is particularly rapidly effected by a drop in blood sugar levels:- hence the symptoms of slurred speech, memory lapses, headaches, loss of co-ordination, blurred vision, personality changes, and so on commonly associated with alcohol consumption.
Monohydrate dextrose breaks down to glucose in the body, and thus both monohydrate dextrose and glucose are quickly and readily assimilated into the blood stream to boost the blood sugar level and help prevent liver damage and counteract brain disfunction.
The presence of alcohol in the system also is believed to increase the amount and frequency of urine passed, leading to a depletion of vitamin C, (ascorbic acid) , magnesium and potassium in the system, and these losses need to be replaced to allow the system to resume functioning correctly. Examples of suitable magnesium and potassium salts are magnesium sulphate, magnesium oxide, and potassium phosphate.
It is believed that the presence in the composition of only minute traces of magnesium and potassium salts will be sufficient to stimulate the release of adequate supplies of these salts from the body's own stores. An alternative explanation of the effectiveness of the compound of the
present invention iε that the body requires only minute traces of the magnesium and potassium salts to make up the deficiencies caused by alcohol. However, a higher proportion of magnesium and potassium salts may be advantageous. One or more potassium salts and one or more magnesium salts may be used.
Also, it is believed that the magnesium and potassium salts and vitamin C are much more readily and easily absorbed into the system if taken into the system with monohydrate dextrose or glucose:- the monohydrate dextrose or glucose effectively coats said other constituents and prevents them from being destroyed by stomach acids, and also speeds their circulation around the system.
Zinc oxide assists the pancreas with the production of insulin, and hence facilitates the absorption of glucose into the blood. Zinc oxide also is known to be effective in detoxifying the system i.e. combatting the after-effects of alcohol.
It is believed that the presence of vitamin B6 in the composition considerably increases the rate of activity of the composition and thus gives more rapid relief to a user. It appears that vitamin B6 and magnesium salts are synergistic i.e. the presence of one increases the effectiveness of the other, and thus reduces the amount of each needed in the composition to achieve the desired effect.
Thus, the constituents of the composition act to raise the user's blood sugar level and replenish lost vitamin C,
magnesium and potassium, and also interact with each other to mutually increase their effectiveness and to speed their assimilation into the system.
Optionally, the composition also may contain one or more of the following:
(a) 0.5% - 2% by weight powdered citric acid, to improve the palatability of the composition;
(b) 0.5% - 5% by weight powdered calcium phosphate, to replenish calcium losses. A preferred embodiment of the present composition comprises:
(a) 2.4% ascorbic acid;
(b) 1.1% citric acid;
(c) 0.4% vitamin B6; (d) 0.1% magnesium sulphate;
(e) 0.1% potassium phosphate;
(f) 0.1% magnesium oxide;
(g) 0.03% zinc oxide;
(h) 95.77% monohydrate dextrose; (all % by weight) .
The composition is in the form of a powder, and is taken dissolved in water or in tablet form. It has been found that the composition is more effective if the user lies on the right side after taking the composition, because this allows the composition to pass more quickly though the duodenum into the intestine, for absorption into the system.
Alternatively, the composition may be prepared in liquid
form, and drunk or given by injection.
Claims
1. A composition including:- a major proportion of monohydrate dextrose or glucose in combination with the following compounds: (a) 0.5% - 2% by weight ascorbic acid;
(b) a non-toxic potassium salt in a homeopathic titration to the 6 C potency or up to 0.4% by weight;
(c) a non-toxic magnesium salt in a homeopathic titration to the 6 C potency or up to 0.4% by weight; (d) 0.001% - 2.5% by weight vitamin B6;
(e) zinc oxide in a homeopathic titration to the 6 C potency or up to 0.07% by weight.
2. The composition as claimed in Claim 1, further including 0.5% - 2% by weight of citric acid.
3. The composition as claimed in Claim 1 or Claim 2 , further including 0.5% - 5% by weight of calcium phosphate.
4. A composition comprising
(a) 2.4% ascorbic acid;
(b) 1.1% citric acid; (c) 0.4% vitamin B6;
(d) 0.1% magnesium sulphate;
(e) 0.1% potassium phosphate;
(f) 0.1% magnesium oxide;
(g) 0.03% zinc oxide; (h) 95.77% monohydrate dextrose;
(all % by weight) .
5. The composition as claimed in any preceding claim, wherein said composition is in the form of a powder.
6. The composition as claimed in any preceding claim, wherein said composition is in the form of a liquid.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94913846A EP0700255A4 (en) | 1993-05-26 | 1994-05-10 | Monohydrate dextrose or glucose composition |
| AU65844/94A AU676314B2 (en) | 1993-05-26 | 1994-05-10 | Monohydrate dextrose or glucose composition |
| CA002162877A CA2162877C (en) | 1993-05-26 | 1994-05-10 | Monohydrate dextrose or glucose composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ247701 | 1993-05-26 | ||
| NZ24770193 | 1993-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1994027449A1 true WO1994027449A1 (en) | 1994-12-08 |
Family
ID=19924357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/NZ1994/000042 WO1994027449A1 (en) | 1993-05-26 | 1994-05-10 | Monohydrate dextrose or glucose composition |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0700255A4 (en) |
| CN (1) | CN1124444A (en) |
| AU (1) | AU676314B2 (en) |
| CA (1) | CA2162877C (en) |
| WO (1) | WO1994027449A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997026897A1 (en) * | 1996-01-24 | 1997-07-31 | Edwina Margaret Piper | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine |
| FR2748936A1 (en) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Composition to lessen alcohol passing into the bloodstream |
| FR2748904A1 (en) * | 1996-05-27 | 1997-11-28 | Turpin Veronique | Personalised nutritional complement containing Schuessler salts |
| WO1999026492A1 (en) * | 1997-11-21 | 1999-06-03 | Turpin Veronique | Nutritional additive based on schuelssler biochemical salts |
| KR100309715B1 (en) * | 1998-04-07 | 2001-12-28 | 이명희 | Composition having function for preventing toxicity and hangover of alcohol by activation of citric acid cycle |
| WO2008156297A2 (en) * | 2007-06-19 | 2008-12-24 | Cj Cheiljedang Corp. | Composition for preventing or treating katzenjammer |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101498780B1 (en) * | 2013-04-18 | 2015-03-04 | 씨제이제일제당 (주) | Composition for preventing or treating hangover |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH370631A (en) * | 1957-05-03 | 1963-07-15 | Heinrich Dr Vogler | Process for the manufacture of a preparation intended as an additive to food and beverages |
| US5132113A (en) * | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
-
1994
- 1994-05-10 AU AU65844/94A patent/AU676314B2/en not_active Ceased
- 1994-05-10 EP EP94913846A patent/EP0700255A4/en not_active Withdrawn
- 1994-05-10 WO PCT/NZ1994/000042 patent/WO1994027449A1/en not_active Application Discontinuation
- 1994-05-10 CA CA002162877A patent/CA2162877C/en not_active Expired - Fee Related
- 1994-05-10 CN CN94192255A patent/CN1124444A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP0700255A4 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997026897A1 (en) * | 1996-01-24 | 1997-07-31 | Edwina Margaret Piper | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine |
| FR2748936A1 (en) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Composition to lessen alcohol passing into the bloodstream |
| FR2748904A1 (en) * | 1996-05-27 | 1997-11-28 | Turpin Veronique | Personalised nutritional complement containing Schuessler salts |
| WO1999026492A1 (en) * | 1997-11-21 | 1999-06-03 | Turpin Veronique | Nutritional additive based on schuelssler biochemical salts |
| KR100309715B1 (en) * | 1998-04-07 | 2001-12-28 | 이명희 | Composition having function for preventing toxicity and hangover of alcohol by activation of citric acid cycle |
| WO2008156297A2 (en) * | 2007-06-19 | 2008-12-24 | Cj Cheiljedang Corp. | Composition for preventing or treating katzenjammer |
| WO2008156297A3 (en) * | 2007-06-19 | 2009-02-19 | Cj Cheiljedang Corp | Composition for preventing or treating katzenjammer |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2162877A1 (en) | 1994-12-08 |
| EP0700255A4 (en) | 1997-02-26 |
| AU6584494A (en) | 1994-12-20 |
| CN1124444A (en) | 1996-06-12 |
| AU676314B2 (en) | 1997-03-06 |
| CA2162877C (en) | 2004-04-13 |
| EP0700255A1 (en) | 1996-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5215750A (en) | L-glutamine and vitamin-containing compositions effective for inducing weight loss and for weight control | |
| US5053396A (en) | Therapeutic composition | |
| EP0669083B1 (en) | Creatine beverage and producing process thereof | |
| Rastogi et al. | Selenium and lead: mutual detoxifying effects | |
| US7498039B2 (en) | Nutritional supplement containing sea water minerals | |
| CA2429117C (en) | Remedy for diabetes mellitus | |
| CA2162877C (en) | Monohydrate dextrose or glucose composition | |
| KR100613618B1 (en) | Method for maintaining oxidative metabolism attendant upon exercise and food for sport | |
| NZ195881A (en) | Pharmaceutical compositions containing cobalt compounds | |
| EP0496479B1 (en) | NADH and NADPH as energy-substitutes | |
| NZ265404A (en) | Composition for treatment of hangover | |
| JP2970957B2 (en) | Refined pollen nutritional preparation | |
| JP2002265365A (en) | Neutrophil function inhibitor | |
| US5348749A (en) | Method for treating panic disorder | |
| JP3241173B2 (en) | Bath additive | |
| US20090062231A1 (en) | Appetite Suppressant Composition and Method of Appetite Suppression | |
| JP2007314560A (en) | Agent for keeping oxidative metabolism caused by exercise | |
| US4474801A (en) | α-Amino-γ-butyrolactones for treating alcohol dependence | |
| US4608256A (en) | Method of treating cachexia | |
| JP2002080376A (en) | Biologically active agent and medicine | |
| KR20120119686A (en) | A functional beverage composition comprising l-arginine, vitamin c, vitamin b complex, vitamin a, vitamin e and potassium iodide as main ingredients | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| JPH0640901A (en) | Agent for suppressing toxicity of acetaldehyde | |
| KR20120110955A (en) | A functional beverage composition comprising taurine, inositol, vitamin c, vitamin b complex, potassium iodide as main ingredients | |
| JPH0414082B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 94192255.3 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 265404 Country of ref document: NZ |
|
| ENP | Entry into the national phase |
Ref document number: 1995 537797 Country of ref document: US Date of ref document: 19951027 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1994913846 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2162877 Country of ref document: CA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1994913846 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1994913846 Country of ref document: EP |